The pharmaceutical industry may be running a smoke screen to prevent alternative treatments from reaching the audience that needs them most, CannaFundr reports.
Post-Traumatic Stress Disorder (PTSD) is a condition that affects more than 7.5 million Americans. People of all ages are affected by the condition, which results in a variety of uncontrollable symptoms stemming from a traumatic event in their life.
PTSD isn’t like many conditions. There’s no silver bullet that guarantees relief, and each treatment plan is unique to the patient. Cognitive behavioral therapy and alternative medications, such as marijuana, have proven highly effective. Despite this, pharmaceutical companies have managed to push a number of their brands to doctors, including Ambien, Zoloft, Prozac, Lexapro, Paxil and others. The list is long, and it doesn’t include cannabis – despite endless stories from real patients proving its efficacy.
The Veteran’s Association and insurance companies typically do not cover medical marijuana, though they happily help out with costs related to Big Pharma drugs – which can easily reach a price tag that more than triples that of medical marijuana.
The system hasn’t been designed to deliver a kickback on cannabis, CannaFundr notes, so it’s only natural that companies are fighting to keep it out of the hands of those who need it most. The effects have been deadly. Many of the pharmaceutical drugs that supposedly allow PTSD patients to lead normal lives result in their death by suicide.
Whether it’s the result of inadequate effect from the prescribed substances or the side effects of the drugs themselves, there is no denying that it’s happening at unsettling rates.
The math is simple: cannabis isn’t as easy to control and capitalize on financially. Naturally, the pharmaceutical companies are doing what they can to slow things down.
Read the whole post for more insight here.